BRIEF-Transition Therapeutics says dosing of first patient in Phase 2 study of drug candidate TT701

Mon Apr 25, 2016 4:14pm EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

April 25 (Reuters) - Transition Therapeutics Inc

* Transition therapeutics announces dosing of first patient in phase 2 study of drug candidate tt701 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)